Data Provided by Refinitiv. Minimum 15 minutes delayed.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
May 26, 2022
May 16, 2022
Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational UpdatesMay 10, 2022